Demographic, Physical, and Psychological Determinants of Patient Experience with Subcutaneous Self-Injection in Patients with Rheumatoid Arthritis: Structural Equation Modeling Approach

1. Watts R, Clunie G, Hall F, Marshall T. Rheumatology (Oxford Desk Reference). Oxford University Press; 2011.

2. Janke K, Biester K, Krause D, et al. Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network

meta-analysis including aggregate results from reanalysed individual patient data. BMJ. 2020;370:m2288. doi:10.1136/bmj.m2288

3. Hamm R, Patel B, Whittlestone T, Persad R. Patient self-injection: a new approach to administering luteinizing hormone-releasing hormone

analogues. BJU Int. 2000;86(7):840–842. doi:10.1046/j.1464-410x.2000.00910.x

4. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6

(1):1–14. doi:10.1002/msc.110

5. Salaffi F, Di Carlo M, Farah S, Carotti M. Adherence to subcutaneous anti-TNFα agents in patients with rheumatoid arthritis is largely influenced by

pain and skin sensations at the injection site. Int J Rheum Dis. 2020;23(4):480–487. doi:10.1111/1756-185x.13803

6. Kageyama G, Onishi A, Ueda Y, et al. Subjective well-being among rheumatoid arthritis patients. Int J Rheum Dis. 2019;22(10):1863–1870.

doi:10.1111/1756-185x.13704

7. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League

Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–1588. doi:10.1136/ard.2010.138461

1558

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/PPA.S413871

DovePress

Patient Preference and Adherence 2023:17

Dovepress

Onishi et al

8. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection

Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2. doi:10.1186/1477-7525-9-2

9. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of

a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806. doi:10.1186/ar1740

10. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–145. doi:10.1002/

art.1780230202

11. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–662. doi:10.1001/

jama.1949.02900430001001

12. Hair JF, Hult GTM, Ringle CM, et al. An Introduction to Structural Equation Modeling. In: Partial Least Squares Structural Equation Modeling

(PLS-SEM) Using R: A Workbook. Cham: Springer International Publishing; 2021:1–29.

13. Byrne BM. Structural Equation Modeling with Amos: Basic Concepts, Applications, and Programming. 3rd ed. Routledge; 2016.

14. van den Bemt BJF, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in

rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384–392. doi:10.1080/

10717544.2019.1587043

15. Kishimoto M, Yamairi F, Sato N, Kobayashi J, Yamauchi S, Iwasaki T. Patient preference for treatment mode of biologics in rheumatoid arthritis:

a 2020 web-based survey in Japan. Rheumatol Ther. 2021;8(3):1095–1111. doi:10.1007/s40744-021-00325-9

16. Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun Rev.

2020;19(6):102528. doi:10.1016/j.autrev.2020.102528

17. Lempp H, Scott D, Kingsley G. The personal impact of rheumatoid arthritis on patients’ identity: a qualitative study. Chronic Illn. 2006;2

(2):109–120. doi:10.1177/17423953060020020601

18. Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during

treatment. Rheumatol Ther. 2017;4(2):445–463. doi:10.1007/s40744-017-0080-4

19. Fernandez JM, Madsen S, Krase JM, Shi VY. Classification and mitigation of negative injection experiences with biologic medications. Dermatol

Ther. 2020;33(2):e13240. doi:10.1111/dth.13240

20. Doumen M, De Cock D, Pazmino S, et al. Treatment response and several patient-reported outcomes are early determinants of future self-efficacy

in rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):269. doi:10.1186/s13075-021-02651-3

21. Bailey K, Mountian I, Bruggraber R, Sunderland K, Tilt N, Szegvari B. Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®)

in the UK. Adv Ther. 2020;37(4):1522–1535. doi:10.1007/s12325-020-01257-6

22. Wray S, Armstrong R, Herrman C, et al. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in

patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opin Drug Deliv. 2011;8(12):1543–1553. doi:10.1517/17425247.2011.628656

Patient Preference and Adherence

Dovepress

Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient

preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and

their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of

interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely

online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read

real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/patient-preference-and-adherence-journal

Patient Preference and Adherence 2023:17

Powered by TCPDF (www.tcpdf.org)

DovePress

1559

...